When do Section 232 pharmaceutical tariffs start?

The proclamation sets July 31, 2026 for companies listed in Annex III and September 29, 2026 for other companies without qualifying treatment. The tariffs are not yet being collected as of the May 8, 2026 review.

What should pharmaceutical importers check first?

Start with the 10-digit HTS classification and Annex I scope. Then determine whether the product is patented, generic, a biosimilar, specialty, U.S.-origin, or otherwise eligible for a lower or zero tariff tier.

Are generic pharmaceuticals subject to the new Section 232 tariff?

Generic pharmaceuticals and associated ingredients are not subject to Section 232 tariffs at this time, but the proclamation directs Commerce to review within one year whether circumstances support action on generic imports.

Does the proclamation allow drawback?

Yes. The proclamation states that drawback is available for duties imposed under the pharmaceutical Section 232 action.

Section 232 Pharma Implementation Checklist

Quick Answer

Section 232 pharmaceutical tariffs are codified but not yet collected as of May 8, 2026. The implementation dates are:

July 31, 2026 for companies listed in Annex III.
September 29, 2026 for other companies without qualifying tariff treatment.

The highest-risk mistake is treating every Chapter 29 or Chapter 30 product as covered. Start with the product's 10-digit HTS code, confirm whether it appears in Annex I, then determine company status, country of origin, product category, and agreement eligibility.

Informational only - not legal advice.

Use this checklist if

Use this page if you import, buy, broker, or model landed cost for:

patented pharmaceuticals,
biologics,
active pharmaceutical ingredients,
key starting materials,
finished dosage products in Chapter 30,
organic-chemical inputs in Chapter 29 that may be tied to patented drugs.

For the full explainer, start with Section 232 Pharmaceutical Tariffs: What Importers Need to Know Before July 31. This checklist is the implementation workpaper.

1. Confirm Annex I scope

Do not start with product names. Start with the classification.

Field	What to capture	Why it matters
Base HTS	Full 10-digit Chapter 29 or 30 classification	Annex I scope is code-specific.
Product identity	Drug, biologic, API, key starting material, or other input	Scope turns on product category and relation to patented pharmaceuticals.
FDA reference	Orange Book, Purple Book, or other support	Helps distinguish patented products from excluded or zero-rate categories.
Entry date	Consumption entry or warehouse withdrawal date	Determines whether the effective date has arrived.
Chapter 99 line	Expected `9903.04.*` heading, if covered	The Chapter 99 line drives Section 232 reporting and duty treatment.

Chapter 29 and 30 are not enough

The proclamation does not make every Chapter 29 or Chapter 30 product subject to a pharmaceutical Section 232 duty. The Annex I 10-digit subheading list is the starting point.

2. Determine the effective-date tranche

Company posture	Effective date
Company listed in Annex III	July 31, 2026
Other company without qualifying treatment	September 29, 2026
Company with pre-existing qualifying agreement or later qualifying treatment	Check the applicable zero-rate or reduced-rate treatment

If a shipment is entered before the applicable effective date, do not model a Section 232 pharma collection event just because the 9903.04.* headings already exist in the HTS.

3. Assign the rate tier

Use the lowest applicable tier only after confirming scope, origin, and company status.

Rate posture	Practical question
Default 100%	Does no company, country, or product-specific lower tier apply?
20% onshoring tier	Has Commerce approved an onshoring plan or assessed likely near-term eligibility?
0% onshoring + MFN tier	Does the company have both qualifying onshoring and HHS MFN pricing treatment?
15% country tier	Is the product from the EU, Japan, South Korea, Switzerland, or Liechtenstein?
10% UK tier	Is the product from the United Kingdom, and has no later Federal Register reduction applied?
0% specialty tier	Does Commerce determine the product qualifies under the specialty-product provision?
0% generic status	Is the product a generic pharmaceutical or associated ingredient not subject at this time?
U.S.-origin product	Is the imported product of U.S. origin?

The proclamation also includes two rate mechanics that matter for landed-cost modeling:

If a product is subject to more than one rate under the proclamation, the lowest applicable rate applies.
For most covered products, the Section 232 duty is calculated so the Column 1 duty plus the Section 232 duty equals the applicable rate, unless the Column 1 rate is already higher. The UK treatment has its own carveout from that mechanic.

4. Watch for required agency implementation

Before the first effective date, monitor for:

CBP CSMS implementation guidance for 9903.04.* entry filing,
Federal Register notices setting onshoring-plan criteria,
Federal Register notices changing rates for countries or companies,
Commerce determinations for specialty pharmaceutical products,
any Federal Register notice reducing the UK rate to zero under a later agreement,
HTS revision updates from USITC,
ACE validation behavior for the new headings.

5. Preserve evidence before the first entry

For each SKU or import program, preserve:

supplier and manufacturer identity,
company group responsible for the drug or ingredient,
country of origin,
FDA product status evidence,
patent/generic/biosimilar status support,
Annex I classification analysis,
applicable agreement or onshoring status,
entry date and planned port,
base duty rate and any existing Section 301 or other Chapter 99 exposure.

Do this before July 31 for Annex III exposure and before September 29 for other exposure. Waiting until the first duty bill arrives makes it harder to separate classification, origin, and company-rate issues.

6. Check FTZ and drawback treatment

The proclamation has two operational details that should be in every implementation memo:

Topic	Rule to preserve
Foreign-trade zones	Covered goods admitted into an FTZ on or after the effective date generally must be admitted as privileged foreign status unless eligible for domestic status.
Drawback	Drawback is available for duties imposed under the pharmaceutical Section 232 action.

These rules affect supply-chain planning and recovery strategy, but they do not eliminate the need to classify and report the correct Chapter 99 line at entry.